Modality
Bispecific Ab
MOA
Menini
Target
EGFR
Pathway
Notch
RBBladder Ca
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
→ Jun 2028
Phase 3Current
NCT05025198
1,910 pts·Bladder Ca
2025-01→2025-10·Recruiting
NCT06054065
2,459 pts·Bladder Ca
2023-05→2028-04·Terminated
NCT04960963
853 pts·Bladder Ca
2019-01→2028-06·Completed
5,222 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-10-215mo agoPh3 Readout· Bladder Ca
2028-04-132.0y awayPh3 Readout· Bladder Ca
2028-06-132.2y awayPh3 Readout· Bladder Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
P3
Termina…
P3
Recruit…
Catalysts
Ph3 Readout
2025-10-21 · 5mo ago
Bladder Ca
Ph3 Readout
2028-04-13 · 2.0y away
Bladder Ca
Ph3 Readout
2028-06-13 · 2.2y away
Bladder Ca
RecruitingCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05025198 | Phase 3 | Bladder Ca | Recruiting | 1910 | UPCR |
| NCT06054065 | Phase 3 | Bladder Ca | Terminated | 2459 | UPDRS |
| NCT04960963 | Phase 3 | Bladder Ca | Completed | 853 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR | |
| Adagraderotide | Olema | Phase 2 | EGFR |